The thoracic oncology community is discussing newly published data from the phase 3 ELEVATE trial, which showed a disease-free survival benefit for adjuvant ensartinib in resected ALK-positive NSCLC. Other conversations focus on targeted therapies for EGFR exon 20 insertion mutations, including zipalertinib, and the role of lung transplant in select patients with stage IV disease.
“lung #transplant following contemporary staging and dissemination-minimizing #surgical technique was associated with higher early overall survival”
— @JAMA_current · Lung transplant in stage IV NSCLC · View post ↗
“24-mo DFS, stage II–IIIB: 86.4% vs 53.5% | HR 0.20”
— @YGaritaonaindia · Adjuvant ensartinib in ALK+ NSCLC · View post ↗📌 Amplified by @KolPulseAI
“Ensartinib beat placebo (~70% of patients got chemo prior), while alectinib beat chemo (more impressive).”
— @UrsWeberMD · Ensartinib trial context · View post ↗
“zipalertinib showed 40% ORR in previously treated EGFR ex20ins NSCLC without prior ex20ins targeted therapy”
— @DAVAOnc · Zipalertinib in EGFR ex20ins NSCLC · View post ↗📌 Amplified by @KolPulseAI
Dana-Farber's Breast Oncology Center highlighted a new secondary analysis of the DAPHNe trial, published in JAMA Oncology. The study evaluates neoadjuvant paclitaxel, trastuzumab, and pertuzumab for patients with stage II to III, ERBB2-positive breast cancer.
“Neoadjuvant THP x12 will likely soon become a SoC for many patients with stage II HER2+ breast cancer. While awaiting confirmation from the CompassHER2-pCR trial, #DAPHNe provides a glimpse of the future 👉96% ultrasensitive ctDNA clearance 👉5y RFI 98%”
— @PTarantinoMD · DAPHNe (neoadjuvant THP, HER2+) · View post ↗
“New @JAMAOnc Study 👉Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial”
— @DFCI_BreastOnc · DAPHNe Trial Secondary Analysis · View post ↗📌 Amplified by @KolPulseAI
The GI oncology community is discussing results from the phase II eNRGy trial of zenocutuzumab in NRG1 fusion–positive cholangiocarcinoma, which showed an ORR of 36.8% and a median PFS of 9.2 months. Separately, multiple physicians noted that the European Medicines Agency (EMA) has initiated a fast-tracked review of daraxonrasib for metastatic pancreatic cancer.
“EMA fast tracks review of a medicine for metastatic #PancreaticCancer The medicine, no surprise, is Daraxonrasib.”
— @Aiims1742 · Daraxonrasib EMA review · View post ↗“Are shorter term observational studies missing a potential deleterious effect of these agents on exocrine neoplasia?”
— @Aiims1742 · GLP-1 agonists and pancreatic cancer · View post ↗
“In the phase II eNRGy trial, zenocutuzumab achieved an ORR of 36.8%, clinical benefit rate of 57.9%, and median PFS of 9.2 months, with no treatment discontinuations due to AEs.”
— @Dr_ElvinaA · eNRGy trial · View post ↗📌 Amplified by @KolPulseAI
“🧐rare GA in BTC, but effective treatment, broad NGS is key”
— @ArndtVogel · Zenocutuzumab in cholangiocarcinoma · View post ↗📌 Amplified by @KolPulseAI
The GU oncology community is discussing new data across the disease spectrum. In localized prostate cancer, a Phase 1/2 trial evaluated single-fraction SBRT. In metastatic prostate cancer, a study identified rare germline CDK12 variants. For urothelial carcinoma, the focus is on biomarkers, with publications on the prognostic implications of ctDNA in patients treated with enfortumab vedotin and a real-world assessment of the HERO score.
“🚨 ONE-SHOT prostate SBRT: Can we treat localized prostate cancer in 1 fraction?☢️”
— @Adam_Weiner535 · Single-fraction prostate SBRT · View post ↗
“➡️ Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab by Kevin R. Reyes ...Vadim S. Koshkin et al”
— @EurUrolOncol · ctDNA in Urothelial Carcinoma · View post ↗
“Comprehensive review on the management of localized bladder cancer in @NatRevClinOncol: from BCG-unresponsive NMIBC to perioperative immunotherapy, bladder-preserving strategies, and the emerging role of ctDNA-guided decisions in MIBC.”
— @drenriquegrande · Localized bladder cancer management · View post ↗
“This study identified rare germline CDK12 truncating variants in 5 of 4,535 patients (0.1%) with metastatic #ProstateCancer , challenging the belief that CDK12🧬 alterations are exclusively somatic.”
— @APCCC_Lugano · Germline CDK12 variants · View post ↗The myeloma/hematology community is discussing early data for the new CELMoD mezigdomide from the SUCCESSOR-2 trial. Concurrently, there is focus on CAR-T therapy side effects, with discussion around a study of immune effector cell-associated enterocolitis (IEC-EC) following cilta-cel. Commentary also continues on the persistent high cost of established therapies like lenalidomide.
“Twenty years after it was first approved for myeloma, lenalidomide is still very expensive: the 4th most drug in terms of Medicare Spend (in 2024).”
— @VincentRK · Lenalidomide cost · View post ↗📌 Amplified by @KolPulseAI
“A New CELMoD Contender: SUCCESSOR-2 Highlights Mezigdomide’s Potential in #Myeloma | EHA 2026”
— @MyelomaTeacher · Mezigdomide in SUCCESSOR-2 · View post ↗📌 Amplified by @KolPulseAI
“Researchers have recently classified immune effector cell-associated enterocolitis (IEC-EC) as an adverse event after CAR-T.”
— @Blood_Cancers · CAR-T toxicity · View post ↗The hematology community is discussing risk prognostication in AML, with attention on the PRISM Risk Model for patients following treatment with hypomethylating agents and venetoclax. In lymphoma, new EBMT recommendations for cellular therapy in mantle cell lymphoma are being shared, alongside updates on the 5th edition WHO classification for diagnosing DLBCL, HGBL, and Burkitt's lymphoma. A study is also exploring TAM-mediated resistance mechanisms to CD19 CAR T cells.
“Full-dose VEN showed comparable effectiveness to azole-adjusted regimens in unfit patients with AML.”
— @BloodPortfolio · AML treatment · View post ↗
“▶️▶️Check out the new open access @TheEBMT recommendations re the use of Cellular therapy in mantle cell lymphoma in @BMTjournal #MCL #lymsm”
— @tobyeyre82 · Mantle Cell Lymphoma · View post ↗📌 Amplified by @KolPulseAI
“Risk Prognostication After Hypomethylating Agents + Venetoclax in AML: PRISM Risk Model”
— @mtmdphd · AML prognostication · View post ↗
“This study reveals active crosstalk between lymphoma cells and M2-like TAMs, as well as TAM-mediated resistance mechanisms to CD19 CAR T cells, which can be circumvented by targeting FR-beta”
— @Hemasphere_EHA · CAR T resistance · View post ↗